KLRS

KALARIS THERAPEUTICS, INC.

KLRS · CIK 1754068 · Annual (10-K) · Last 5 years

Financial Trends

Revenue
20202024
Net Income−$59M
20202024
Operating CF−$68M
20202024
Free Cash Flow
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue————$0.0B
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.0B$0.1B$0.1B$0.1B$0.0B
SG&A Expense—————
Operating Income$-0.1B$-0.2B$-0.2B$-0.2B$-0.1B
Net Income$-0.1B$-0.2B$-0.2B$-0.2B$-0.1B
EPS (Basic)$-11.73$-1.83$-2.20——
EPS (Diluted)$-11.73$-1.83$-2.20——

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.1B$0.2B$0.3B$0.3B$0.4B
Current Assets$0.1B$0.2B$0.2B$0.3B$0.4B
Cash & Equivalents$0.1B$0.1B$0.1B$0.2B$0.1B
Total Liabilities$0.0B$0.0B$0.1B$0.1B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.1B$0.1B$0.2B$0.2B$0.4B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$0.1B$0.0B$-0.1B$0.2B$-0.2B
Capital Expenditures——$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.1B$0.1B$0.0B$0.3B
← Companies